Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.

Bansal N, Davis S, Tereshchenko I, Budak-Alpdogan T, Zhong H, Stein MN, Kim IY, Dipaola RS, Bertino JR, Sabaawy HE.

Prostate. 2014 Feb;74(2):187-200. doi: 10.1002/pros.22740. Epub 2013 Oct 24.

2.

Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells.

Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG.

Cancer Res. 2007 Jul 15;67(14):6796-805. Erratum in: Cancer Res. 2007 Sep 15;67(18):8973.

3.

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.

Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG.

Cell Stem Cell. 2012 May 4;10(5):556-69. doi: 10.1016/j.stem.2012.03.009.

4.

MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.

Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM, Chen YL.

Carcinogenesis. 2013 Mar;34(3):530-8. doi: 10.1093/carcin/bgs371. Epub 2012 Nov 26.

PMID:
23188675
5.

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636. Epub 2011 Jun 13.

6.

BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.

Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon YC, Zhong H, Medina DJ, Kerrigan J, Stein MN, Kim IY, Davis TW, DiPaola RS, Bertino JR, Sabaawy HE.

Clin Cancer Res. 2016 Dec 15;22(24):6176-6191. doi: 10.1158/1078-0432.CCR-15-3107. Epub 2016 Jun 15.

PMID:
27307599
7.

Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.

Zhang L, Jiao M, Li L, Wu D, Wu K, Li X, Zhu G, Dang Q, Wang X, Hsieh JT, He D.

J Cancer Res Clin Oncol. 2012 Apr;138(4):675-86. doi: 10.1007/s00432-011-1146-2. Epub 2012 Jan 12.

PMID:
22237455
8.

Early human prostate adenocarcinomas harbor androgen-independent cancer cells.

Fiñones RR, Yeargin J, Lee M, Kaur AP, Cheng C, Sun P, Wu C, Nguyen C, Wang-Rodriguez J, Meyer AN, Baird SM, Donoghue DJ, Haas M.

PLoS One. 2013 Sep 25;8(9):e74438. doi: 10.1371/journal.pone.0074438. eCollection 2013.

9.

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.

Liu X, Chen X, Rycaj K, Chao HP, Deng Q, Jeter C, Liu C, Honorio S, Li H, Davis T, Suraneni M, Laffin B, Qin J, Li Q, Yang T, Whitney P, Shen J, Huang J, Tang DG.

Oncotarget. 2015 Sep 15;6(27):23959-86.

10.

Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.

Mahdian R, Nodouzi V, Asgari M, Rezaie M, Alizadeh J, Yousefi B, Shahrokh H, Abolhasani M, Nowroozi M.

Mol Biol Rep. 2014 Sep;41(9):6125-31. doi: 10.1007/s11033-014-3491-0. Epub 2014 Jul 2.

PMID:
24985972
11.

Rapid adherence to collagen IV enriches for tumour initiating cells in oral cancer.

Liang X, Osman TA, Sapkota D, Neppelberg E, Lybak S, Liavaag PG, Johannessen AC, Jacobsen HK, Enger PØ, Costea DE, Wang J.

Eur J Cancer. 2014 Dec;50(18):3262-70. doi: 10.1016/j.ejca.2014.09.010. Epub 2014 Oct 10.

12.

ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F, Ansieau S.

Mol Cancer. 2014 Sep 12;13:213. doi: 10.1186/1476-4598-13-213.

13.

TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.

Swanson TA, Krueger SA, Galoforo S, Thibodeau BJ, Martinez AA, Wilson GD, Marples B.

Prostate. 2011 Oct 1;71(14):1548-58. doi: 10.1002/pros.21371. Epub 2011 Mar 10.

PMID:
21394739
14.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
15.

miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.

Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY, Chiou SH.

Cancer Res. 2013 Jun 1;73(11):3425-40. doi: 10.1158/0008-5472.CAN-12-3840. Epub 2013 Apr 2. Erratum in: Cancer Res. 2015 Jul 1;75(13):2761.

16.

CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.

Gravina GL, Mancini A, Muzi P, Ventura L, Biordi L, Ricevuto E, Pompili S, Mattei C, Di Cesare E, Jannini EA, Festuccia C.

Prostate. 2015 Sep;75(12):1227-46. doi: 10.1002/pros.23007. Epub 2015 Jun 12.

PMID:
26073897
17.

ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.

Wang L, Li Y, Yang X, Yuan H, Li X, Qi M, Chang YW, Wang C, Fu W, Yang M, Zhang J, Han B.

Prostate. 2014 May;74(6):647-58. doi: 10.1002/pros.22783. Epub 2014 Jan 16.

PMID:
24435928
18.

Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.

Flajollet S, Tian TV, Flourens A, Tomavo N, Villers A, Bonnelye E, Aubert S, Leroy X, Duterque-Coquillaud M.

Mol Cancer Res. 2011 Jul;9(7):914-24. doi: 10.1158/1541-7786.MCR-10-0537. Epub 2011 Jun 13.

19.

In vitro enrichment of ovarian cancer tumor-initiating cells.

House CD, Hernandez L, Annunziata CM.

J Vis Exp. 2015 Feb 18;(96). doi: 10.3791/52446.

20.

Tumorigenic potential of circulating prostate tumor cells.

Carvalho FL, Simons BW, Antonarakis ES, Rasheed Z, Douglas N, Villegas D, Matsui W, Berman DM.

Oncotarget. 2013 Mar;4(3):413-21.

Supplemental Content

Support Center